1. Home
  2. Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults

Author/s: 
Kumar, A, Nalawade, V, Riviere, P, Sarkar, RR, Parsons, JK, Murphy, JD, Rose, BS
Date Added: 
October 19, 2019
Journal/Publication: 
JAMA Network Open
Publisher: 
American Medical Association
Publication Date: 
October 18, 2019
URL: 
Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
Type: 
Clinical Research Results
Format: 
Article
DOI (1): 
10.1001/jamanetworkopen.2019.13612
PMID (1): 
31626312
Keywords 
prostate cancer
5-alpha-reductase inhibitors
5α-Reductase Inhibitors
5-ARIs
prostate-specific antigen
PSA
MeSH 
Humans
male
Prostate-Specific Antigen
Dutasteride
Finasteride
risk factors
prostatic neoplasms
Prostactic Hyperplasia

RPR Commentary

5-alpha-reductase inhibitors reduce PSA levels, even in patients with prostate cancer, so beware.  James W. Mold, MD, MPH

Abstract

5α-reductase inhibitors (5-ARIs) are used to treat benign prostatic enlargement, a common condition causing urinary outflow obstruction. They also reduce prostate-specific antigen (PSA) by approximately 50%. Our group has recently published that among US military veterans, 5-ARIs are associated with delays in prostate cancer (PC) diagnoses, higher grade and stage at presentation, and worse PC-specific mortality (PCSM), presumably because of misinterpreted PSA values. We hypothesized that these results are generalizable to the broader US population.

Text Availability

Free full text